Epilepsy Seizure Brain-and neuroinflammation Translocator protein or peripheral benzodiazepine receptor Microglia 18 F-PBR111 PET Aims: A hallmark in the neuropathology of temporal lobe epilepsy is brain inflammation which has been suggested as both a biomarker and a new mechanistic target for treatments. The translocator protein (TSPO), due to its high upregulation under neuroinflammatory conditions and the availability of selective PET tracers, is a candidate target. An important step to exploit this target is a thorough characterisation of the spatiotemporal profile of TSPO during epileptogenesis. Methods: TSPO expression, microglial activation, astrocyte reactivity and cell loss in several brain regions were evaluated at five time points during epileptogenesis, including the chronic epilepsy phase in the kainic acidinduced status epilepticus (KASE) model (n = 52) and control Wistar Han rats (n = 33). Seizure burden was also determined in the chronic phase. Furthermore, 18 F-PBR111 PET/MRI scans were acquired longitudinally in an additional four KASE animals. Results: TSPO expression measured with in vitro and in vivo techniques was significantly increased at each time point and peaked two weeks post-SE in the limbic system. A prominent association between TSPO expression and activated microglia (p b 0.001; r = 0.7), as well as cell loss (p b 0.001; r = −0.8) could be demonstrated. There was a significant positive correlation between spontaneous seizures and TSPO upregulation in several brain regions with increased TSPO expression. Conclusions: TSPO expression was dynamically upregulated during epileptogenesis, persisted in the chronic phase and correlated with microglia activation rather than reactive astrocytes. TSPO expression was correlating with spontaneous seizures and its high expression during the latent phase might possibly suggest being an important switching point in disease ontogenesis which could be further investigated by PET imaging.
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Introduction
Epilepsy is one of the most common chronic neurological disorders with an estimated prevalence of about 65 million people worldwide (Ngugi et al., 2010) . It has a devastating impact on the patients' everyday life as it is characterised by spontaneous recurrent seizures (SRS) due to aberrant neuronal excitation. The medicinal therapies available are purely symptomatic, have significant side effects and are ineffective in up to 30% of the patients. Furthermore, the neurobiological processes that result in (acquired) epilepsy remain unclear, which strongly impedes the development of more potent, targeted and efficient treatments. Interestingly, immune-challenging insults like fever, infection
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Abbreviations: 3-D, three-dimensional; CA, cornu ammonis; CT, computed tomography; DG, dentate gyrus; DH, dentate hilus; GFAP, glial fibrillary acid protein; KA, kainic acid; KASE, kainic acid-induced status epilepticus; MR, magnetic resonance; MRI, magnetic resonance imaging; OD, optical density; PBS, phosphate buffered saline; PET, positron emission tomography; ROI, region of interest; s.c., subcutaneous; SE, status epilepticus; SRS, spontaneous recurrent seizures; TLE, temporal lobe epilepsy; TSPO, translocator protein; vEEG, video-electroencephalography; VOI, volume of interest.
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